@article{ART003234959},
author={Bong-Keun Jang and Ala Aiob and Dong Hoon Suh and Kidong Kim and Jae Hong No and Hye-Yeoun Kang and Sunyoung Park and Yong Beom Kim},
title={Exploring the Anti-cancer Potential of the New BRD4 Inhibitor, OPT-0139, in Human Hepatic Carcinoma},
journal={CELLMED},
issn={3022-6805},
year={2025},
volume={15},
number={10},
pages={18-27},
doi={10.5667/CellMed.2025.012}
TY - JOUR
AU - Bong-Keun Jang
AU - Ala Aiob
AU - Dong Hoon Suh
AU - Kidong Kim
AU - Jae Hong No
AU - Hye-Yeoun Kang
AU - Sunyoung Park
AU - Yong Beom Kim
TI - Exploring the Anti-cancer Potential of the New BRD4 Inhibitor, OPT-0139, in Human Hepatic Carcinoma
JO - CELLMED
PY - 2025
VL - 15
IS - 10
PB - Cellmed Orthocellular Medicine and Pharmaceutical Association
SP - 18
EP - 27
SN - 3022-6805
AB - Objective: Bromodomain-containing protein 4 (BRD4) is integral to the regulation of cell growth and differentiation. Inhibition of BRD4 can impede the expression of its associated genes, thereby suppressing cancer cell growth. This study investigates the potential anti-cancer properties of OPT-0139, a novel inhibitor targeting BRD4.
Method: Human hepatic carcinoma cell lines (SK-Hep1 and Huh-7) were employed to explore the impact of OPT-0139 treatment, both singly and in combination with Sorafenib. Cell viability, proliferation, cell cycle arrest, and apoptotic cell death were assessed using MTT and ATP assays, flow cytometry, Annexin V assay, and caspase-3 activity assay. The expression of BRD4 and apoptosis-related molecules was evaluated via RT-PCR and Western blot. An in vivo experiment utilizing a mouse xenograft model analyzed tumor growth, weight, and mRNA levels.
Results: OPT-0139 significantly reduces cell viability and proliferation, inducing cell cycle arrest and apoptotic cell death. The mouse xenograft model demonstrates significant alterations in tumor growth and the expression of BRD4 and apoptosis-related proteins. Combined treatment with Sorafenib synergistically enhances apoptotic cell death and suppresses tumor growth, both in vitro and in vivo.
Conclusion: This investigation validates OPT-0139's efficacy and mechanism in human hepatic carcinoma cell lines. The study underscores OPT-0139's potential as a promising therapeutic agent for human hepatocellular carcinoma.
KW - BRD4 inhibitor;hepatocellular carcinoma;OPT-0139;anti-cancer potential
DO - 10.5667/CellMed.2025.012
ER -
Bong-Keun Jang, Ala Aiob, Dong Hoon Suh, Kidong Kim, Jae Hong No, Hye-Yeoun Kang, Sunyoung Park and Yong Beom Kim. (2025). Exploring the Anti-cancer Potential of the New BRD4 Inhibitor, OPT-0139, in Human Hepatic Carcinoma. CELLMED, 15(10), 18-27.
Bong-Keun Jang, Ala Aiob, Dong Hoon Suh, Kidong Kim, Jae Hong No, Hye-Yeoun Kang, Sunyoung Park and Yong Beom Kim. 2025, "Exploring the Anti-cancer Potential of the New BRD4 Inhibitor, OPT-0139, in Human Hepatic Carcinoma", CELLMED, vol.15, no.10 pp.18-27. Available from: doi:10.5667/CellMed.2025.012
Bong-Keun Jang, Ala Aiob, Dong Hoon Suh, Kidong Kim, Jae Hong No, Hye-Yeoun Kang, Sunyoung Park, Yong Beom Kim "Exploring the Anti-cancer Potential of the New BRD4 Inhibitor, OPT-0139, in Human Hepatic Carcinoma" CELLMED 15.10 pp.18-27 (2025) : 18.
Bong-Keun Jang, Ala Aiob, Dong Hoon Suh, Kidong Kim, Jae Hong No, Hye-Yeoun Kang, Sunyoung Park, Yong Beom Kim. Exploring the Anti-cancer Potential of the New BRD4 Inhibitor, OPT-0139, in Human Hepatic Carcinoma. 2025; 15(10), 18-27. Available from: doi:10.5667/CellMed.2025.012
Bong-Keun Jang, Ala Aiob, Dong Hoon Suh, Kidong Kim, Jae Hong No, Hye-Yeoun Kang, Sunyoung Park and Yong Beom Kim. "Exploring the Anti-cancer Potential of the New BRD4 Inhibitor, OPT-0139, in Human Hepatic Carcinoma" CELLMED 15, no.10 (2025) : 18-27.doi: 10.5667/CellMed.2025.012
Bong-Keun Jang; Ala Aiob; Dong Hoon Suh; Kidong Kim; Jae Hong No; Hye-Yeoun Kang; Sunyoung Park; Yong Beom Kim. Exploring the Anti-cancer Potential of the New BRD4 Inhibitor, OPT-0139, in Human Hepatic Carcinoma. CELLMED, 15(10), 18-27. doi: 10.5667/CellMed.2025.012
Bong-Keun Jang; Ala Aiob; Dong Hoon Suh; Kidong Kim; Jae Hong No; Hye-Yeoun Kang; Sunyoung Park; Yong Beom Kim. Exploring the Anti-cancer Potential of the New BRD4 Inhibitor, OPT-0139, in Human Hepatic Carcinoma. CELLMED. 2025; 15(10) 18-27. doi: 10.5667/CellMed.2025.012
Bong-Keun Jang, Ala Aiob, Dong Hoon Suh, Kidong Kim, Jae Hong No, Hye-Yeoun Kang, Sunyoung Park, Yong Beom Kim. Exploring the Anti-cancer Potential of the New BRD4 Inhibitor, OPT-0139, in Human Hepatic Carcinoma. 2025; 15(10), 18-27. Available from: doi:10.5667/CellMed.2025.012
Bong-Keun Jang, Ala Aiob, Dong Hoon Suh, Kidong Kim, Jae Hong No, Hye-Yeoun Kang, Sunyoung Park and Yong Beom Kim. "Exploring the Anti-cancer Potential of the New BRD4 Inhibitor, OPT-0139, in Human Hepatic Carcinoma" CELLMED 15, no.10 (2025) : 18-27.doi: 10.5667/CellMed.2025.012
